Macrosalb Medi-Radiopharma (Human Albumin As Macroaggregates)

Human Albumin Macroaggregates are labeled with technetium‑99m and form microscopic particles that, after intravenous injection, become temporarily trapped in the pulmonary capillaries. The trapped particles emit gamma radiation, creating a map of perfused lung areas that can be captured by a gamma camera, allowing clinicians to visualize and quantify lung blood flow.

The dose of Macrosalb Medi‑Radiopharma is determined by the prescribing nuclear medicine physician based on the specific imaging protocol, patient weight, and the required image quality. The prescriber selects the appropriate activity (megabecquerels) to achieve optimal lung perfusion visualization while adhering to radiation safety guidelines.

The pregnancy category for Macrosalb is listed as unknown. Use during pregnancy or lactation should only occur when the diagnostic benefit outweighs any potential risk to the fetus or infant. The prescribing physician should evaluate the clinical necessity and discuss possible alternatives with the patient.

To order Macrosalb Medi‑Radiopharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Macrosalb contains human albumin macroaggregates labeled with technetium‑99m, which is the standard agent for lung perfusion imaging. Compared with alternative agents, it offers consistent particle size distribution and reliable capillary trapping, providing high‑quality images. Its safety profile is comparable to other technetium‑99m macroaggregated albumin products, with similar rates of mild adverse reactions.

Macrosalb should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures the radiolabel remains stable and the product retains its intended performance for imaging.

Macrosalb is administered by slow intravenous injection, typically as a bolus through a peripheral vein. The injection is performed by qualified healthcare personnel in a nuclear medicine department, and patients are monitored for a short period after administration to observe any immediate reactions before proceeding with the imaging study.

The most serious risks include severe allergic reactions such as anaphylaxis, acute pulmonary hypertension, and rare embolic events that can obstruct larger pulmonary vessels. These events require immediate medical intervention. Clinicians should be prepared to manage hypersensitivity and monitor patients closely during and after injection.

Macrosalb should be avoided in patients with a known hypersensitivity to human albumin, albumin‑based products, or any component of the radiopharmaceutical. It is also contraindicated in individuals with severe pulmonary hypertension, uncontrolled right‑heart failure, or those who have experienced serious reactions to previous macroaggregated albumin studies.